方法：对11例11眼新生血管性青光眼患者行康柏西普玻璃体腔注射，观察房角及虹膜新生血管消退后，行复合式小梁切除术，所有患者均在合适的时机行全视网膜光凝术。术后平均随防6mo，观察术后视力、眼压及并发症等情况。

结果：术后眼压与术前比较，术后1wk，1、3、6mo眼压均有下降，且差异有统计学意义(P<0.01)。术后6mo，2眼(18%)矫正视力提高，8眼(73%)视力无明显变化，1眼(9%)视力降低。术后并发症主要包括前房积血、浅前房、玻璃体积血等。

结论：康柏西普玻璃体腔注射联合全视网膜光凝术和复合式小梁切除术综合治疗新生血管性青光眼能有效控制眼压，保护视功能。

METHODS: Eleven patients(11 eyes)with neovascular glaucoma were injected with conbercept 0.50mg/0.05mL in vitreous chamber. Complex trabeculectomy was performed after the neovascularization dissipated, and PRP was performed in all cases at the right time. The follow-up time was 6mo. The vision, intraocular pressure(IOP)and complications were observed after complex trabeculectomy.

RESULTS: The IOP were all decreased at 1wk, 1, 3 and 6mo after operation, and the difference was statistically significant(P<0.01). After 6mo, the best-corrected visual acuity of 2 eyes(18%)was improved, 8 eyes(73%)were stable, and 1 eye(9%)was declined. The postoperative complications included hyphema, shallow anterior chamber, and vitreous hemorrhage.

CONCLUSION: Intravitreous injection of conbercept combined with complex trabeculectomy and PRP can control the IOP and preserve the visual function effectively in patients with neovascular glaucoma.